^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Three-Year Follow-Up of Neoadjuvant Programmed Cell Death Protein-1 Inhibitor (Sintilimab) in NSCLC

Published date:
05/09/2022
Excerpt:
Two doses of sintilimab (intravenously, 200 mg) were used for patients with stages IA to IIIB NSCLC....In patients with positive PD-L1 expression, 3-year OS and DFS rates were 95.5% and 81.8%, respectively….According to the analysis based on DFS and EFS, our results indicated that patients with higher TMB could have more favorable clinical outcomes than patients with lower TMB (DFS, HR = 0.164 [95% CI: 0.019–1.414]...based on the 3-year follow-up, we are the first to present the long-term and comprehensive survival data for patients with NSCLC receiving PD-1 inhibitors as the neoadjuvant therapy, indicating the efficacy and feasibility of neoadjuvant sintilimab, especially for patients with high TMB and positive PD-L1 expression.
DOI:
https://doi.org/10.1016/j.jtho.2022.04.012